Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates

Affiliations

• ¹ Sol Sherry Thrombosis Research Center, Temple University Medical School, Philadelphia, PA, USA. wxiao@temple.edu.
• ² Department of Microbiology and Immunology, Temple University Medical School, Philadelphia, PA, USA. wxiao@temple.edu.
• ³ Cardiovascular Research Center, Temple University Medical School, Philadelphia, PA, USA. wxiao@temple.edu.
• ⁴ Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA. guangping.gao@umassmed.edu.
• ⁵ Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL, USA. lingchen@peds.ufl.edu.
• ⁶ Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL, USA. rherzog@ufl.edu.
• ⁷ Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. xxiao@email.unc.edu.
• ⁸ State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China. xxiao@email.unc.edu.
• ⁹ Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. rjs@med.unc.edu.